Evidence map›Paper›PMID 28631218›Full record

Observational studyAdvances in therapy2017

An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.

Rejko Krüger, Paul Lingor, Triantafyllos Doskas, Johanna M L Henselmans, Erik H Danielsen, Oriol de Fabregues, Alessandro Stefani, Sven-Christian Sensken, Juan Carlos Parra, Koray Onuk and 2 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Advances in therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Effects of levodopa/carbidopa intestinal gel infusion on autonomic symptoms in advanced Parkinson's disease: a systematic review.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025
    Pooled it
  2. Pooled it
  3. Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2021
    Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Observational
  11. Observational
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 8 countries.

Rejko KrügerLuxembourg Center for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. rejko.krueger@uni.lu.
Paul LingorUniversity Medical Center Göttingen, Göttingen, Germany.
Triantafyllos DoskasNaval Hospital of Athens, Athens, Greece.
Johanna M L HenselmansAntonius Hospital Woerden and Leiden University Medical Center, Leiden, The Netherlands.
Erik H DanielsenDepartment of Neurology, Aarhus University Hospital, Aarhus, Denmark.
Oriol de FabreguesDepartment of Neurology, Vall d'Hebron University Hospital, Neurodegenerative Diseases Group, Vall d'Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain.
Alessandro StefaniParkinson Center, Department System Medicine, Fondazione Policlinico Tor Vergata, Rome, Italy.
Sven-Christian SenskenAbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany.
Juan Carlos ParraAbbVie Inc, 1 Waukegan Road, North Chicago, IL, USA.
Koray OnukAbbVie Inc, 1 Waukegan Road, North Chicago, IL, USA.
Ashley YeginAbbVie Inc, 1 Waukegan Road, North Chicago, IL, USA.
Angelo AntoniniParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, IRCCS Hospital San Camillo, Venice, Italy.
AbbVie (United States) · USAarhus University Hospital · DKAbbVie (Germany) · DEAthens Naval & Veterans Hospital · GRLeiden University Medical Center · NLPoliclinico Tor Vergata · ITUniversitätsmedizin Göttingen · DEUniversity of Luxembourg · LUUniversity of Padua · ITVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionContinuous delivery of levodopa-carbidopa intestinal gel (LCIG) by percutaneous endoscopic gastrojejunostomy (PEG-J) in advanced Parkinson's disease (PD) patients reduces variability in plasma levels, providing better control of motor fluctuations ("on" and "off" states). The MONOTREAT study assessed the effect of LCIG on activities of daily living, motor and non-motor symptoms, and quality of life in advanced PD patients.

methodsThis prospective, observational study included patients with advanced, levodopa-responsive PD with either 2-4 h of "off" time or 2 h of dyskinesia daily. Patients received LCIG via PEG-J for 16 h continuously. Effectiveness was assessed using Unified PD Rating Scale parts II and III, the Non-Motor Symptom Scale, and the PD Questionnaire-8.

resultsThe mean (SD) treatment duration was 275 (157) days. Patients experienced significant improvement from baseline in activities of daily living at final visit (p < 0.05) as well as at months 3 and 6 (p < 0.0001). Patients also experienced significant improvements from baseline in quality of life and non-motor symptoms at all time points (p < 0.001 for all). Specifically, patients manifested significant improvements in mean change from baseline at every study visit in five of nine non-motor symptom score domains: sleep/fatigue, mood/cognition, gastrointestinal tract, urinary, and miscellaneous. One-third of patients (32.8%) experienced an adverse event; 21.9% experienced a serious adverse event; 11.1% discontinued because of an adverse event.

conclusionThis study demonstrated significant and clinically relevant improvements in measures of activities of daily living, quality of life, and a specific subset of non-motor symptoms after treatment with LCIG.

fundingAbbVie Inc.

Indexed as

Quality of LifeActivities of Daily LivingAgedAntiparkinson AgentsCarbidopaDrug CombinationsFemaleGelsHumansLevodopaMaleMiddle AgedParkinson DiseaseProspective StudiesAntiparkinson AgentsCarbidopaDrug CombinationsGelsLevodopaActivities of daily livingLevodopa–carbidopa intestinal gelParkinson’s diseasePercutaneous endoscopic gastrojejunostomyQuality of life

Identifiers

PMID28631218
PMCPMC5504221
OpenAlexW2690927748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.